Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye. After anesthetic had been topically administered, the patient received intravitreal injections of 1,200 micrograms of foscarnet. Plasma and vitreous foscarnet levels were measured by high-performance liquid chromatography. Systemic absorption of the drug was not evident. Elimination half-life from the vitreous after one injection was 54.0 hours. Vitreous levels remained above the mean 50% inhibition value for cytomegalovirus for approximately 56 hours and above the mean inhibition value for human immunodeficiency virus for approximately 241 hours. The patient's visual acuity improved from 20/30 to 20/25 in the left eye. Ophthalmoscopy showed the retinal lesion to have become inactive, and no reactivation occurred during the follow-up period of more than four months. The drug was well tolerated and no retinal toxicity was evident. We suggest an induction treatment regimen of two injections weekly for three weeks, followed by a maintenance treatment regimen of one injection weekly.
Díaz-Llopis
M
M
Department of Ophthalmology, La Fe Hospital, University of Valencia School of Medicine, Spain.
Chipont
E
E
Sanchez
S
S
España
E
E
Navea
A
A
Menezo
J L
JL
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D015828:Eye Infections, Viral / Q000188:drug therapy*; D005500:Follow-Up Studies; D017245:Foscarnet / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D012173:Retinitis / Q000188:drug therapy* / Q000382:microbiology; D014822:Vitreous Body / Q000378:metabolism
D017245:Foscarnet